6533b824fe1ef96bd127fe14

RESEARCH PRODUCT

D-Dimer, Thrombin-Antithrombin III-Komplex (TAT) und Prothrombinfragment 1+2 (PTF)

A. RestP. BrockerhoffM. HofmannL S WeilemannG HafnerB Tanner

subject

Prothrombin timemedicine.medical_specialtymedicine.diagnostic_testmedicine.drug_classbusiness.industryPROTHROMBIN FRAGMENT 1.2Low molecular weight heparinGeneral MedicineHeparinThrombin timeFibrinogenAnesthesiology and Pain MedicineEndocrinologyInternal medicineD-dimermedicinebusinessmedicine.drugPartial thromboplastin time

description

Two groups of 15 patients each with disseminated intravascular coagulation in association with septic disease were treated with low-molecular-weight heparin (lmw-heparin) in different dosages (group I: 1.5-5 IE/kg body weight (BW) per hour; group II: 8-15 IE/kg BW). We studied the levels of D-dimer, thrombin-antithrombin III complex (TAT), prothrombin fragments 1 and 2 (PTF), and global tests of coagulation like prothrombin time (PT), activated partial thromboplastin time (PTT), thrombin time (TT) and platelet count, plasminogen activation (PA) and fibrinogen concentration to estimate the success of heparin therapy in the two groups. TT and fibrinogen concentration were not suitable to follow the course of the coagulation disorder, PT, PTT, platelet count progressively PA, D-dimer, TAT, and PTF normalised progressively after heparinisation. However, only the last three parameters were sensitive enough to show different effects of variable dosages of lmw-heparin. D-dimer, TAT, and PTF levels declined in proportion with heparin concentrations, and thus appear to be the most useful parameters for monitoring the therapeutic effect of heparin in septic coagulopathies.

https://doi.org/10.1007/s001010050455